NEW YORK (GenomeWeb) – Caribou Biosciences announced today that it has signed a deal under which it will use its CRISPR/Cas 9 gene-editing technology for the discovery and validation of new drug targets for Novartis.

Concurrent with the agreement, Novartis has also taken an undisclosed equity stake in Caribou through a Series A investment round.

Caribou will receive research funding from Novartis under the one-year term of the agreement, and it has also provided Novartis with an option to non-exclusively license its CRISPR/Cas 9 platform for research applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).